查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1861366

琥珀酸氟伐曲坦锭：全球市场份额和排名、总收入和需求预测（2025-2031 年）

Frovatriptan Succinate Tablets - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 122 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球氟伐曲坦琥珀酸盐片剂市场规模估计为 3,115 万美元，预计到 2031 年将成长至 3,955 万美元，2025 年至 2031 年的复合年增长率为 3.5%。

本报告全面评估了跨境产业布局、资本配置模式、区域经济相互依存关係以及供应链重组与近期关税调整和国际对琥珀酸氟伐曲坦片采取的战略反制措施之间的关係。

琥珀酸氟伐曲坦锭是一种选择性5-HT1B/1D受体促效剂，主要用于治疗急性偏头痛发作。其上游供应链涉及高纯度活性药物原料药（API）和化学中间体的合成，这些成分主要来自欧洲和印度的专业API生产商。乳糖、淀粉和微晶纤维素等药用辅料则由全球主要的辅料供应商提供。

下游客户主要包括神经科、头痛诊所、零售药局和线上处方平台。随着偏头痛患者数量的增加以及对有效治疗方法需求的成长，琥珀酸氟伐曲坦锭在欧洲、美洲和亚洲市场的需求均稳定成长。未来，随着个人化医疗和远端医疗医疗处方服务的兴起，该药物在全球医疗保健领域的应用范围有望进一步扩大。

预计到 2024 年，琥珀酸氟伐曲坦锭的全球平均价格约为每片 3.74 美元，总销售量将达到约 833 万片。

目前，琥珀酸氟伐曲坦锭的全球市场呈现两极化的格局，既有品牌药也有非专利药，已发展成为曲坦类偏头痛药物中一个成熟的细分市场。在美国和欧洲等已开发市场，受临床指引推荐和广泛医保覆盖的推动，市场需求保持稳定。同时，由于本土非专利生产商的进入，提高了药物的可及性和可负担性，亚太地区（尤其是中国和印度）的市场渗透率正在加速成长。整体而言，市场竞争主要体现在价格策略和分销网络的扩张。

从生产角度来看，琥珀酸氟伐曲坦锭剂的生产需要高度精确的配方製程。常用辅料包括一水乳糖、微晶纤维素、胶体二氧化硅、羧甲基淀粉钠、硬脂酸镁和专用薄膜预混合料。这些辅料对于确保药物的稳定性、生物利用度和患者依从性至关重要，凸显了严格的品管和遵守现行药品生产规范 (CGMP) 标准的重要性。 Endo Pharmaceuticals、Menarini、Ingenus Pharmaceutical 和 Glenmark 等公司拥有先进的生产设施和完善的品管体系，以确保稳定的供应和符合法规要求。原料供应链分为原料药(API) 和辅料两部分，每部分都需要经过严格的药典测试，这给扩大生产规模和实现全球分销带来了复杂的挑战。

展望未来，市场预计将保持相对稳定并实现温和成长。一方面，由于偏头痛盛行率上升以及新兴市场诊断和治疗率的提高，市场需求预计将保持稳定。另一方面，CGRP单株抗体和口服CGRP拮抗剂等新型治疗方法的引入，对传统曲坦类药物构成了替代压力。虽然氟伐曲坦及其相关药物在成熟市场的市场份额可能会逐渐下降，但在医疗覆盖范围有限且对成本较为敏感的地区，预计它们仍将保持强劲的市场地位。主要成长要素包括临床指引中对曲坦类药物的持续采纳、全球偏头痛负担的加重以及学名药的成本优势。然而，市场也面临许多挑战，包括来自新兴治疗领域的竞争威胁、严格的定价和处方法规结构，以及与副作用和联合治疗需求相关的患者依从性问题。这些趋势共同塑造未来的市场机会和竞争格局。

本报告旨在对全球琥珀酸氟伐曲坦片市场按地区/国家、类型和应用进行全面分析，重点关注总销售量、收入、价格、市场份额和主要企业的排名。

本报告以销售量（千片）和收入（百万美元）为单位，对琥珀酸氟伐曲坦片市场规模、估算和预测进行了呈现，基准年为2024年，并涵盖了2020年至2031年的历史数据和预测数据。报告采用定量和定性分析相结合的方法，帮助读者制定琥珀酸氟伐曲坦的业务/成长策略，评估市场竞争，分析自身在当前市场中的地位，并做出明智的商业决策。

市场区隔

公司

  • Endo International
  • Menarini
  • Ingenus Pharmaceutical
  • Glenmark Pharmaceuticals
  • SK Chemicals
  • Teva
  • GL Pharma
  • Clydesdale Pharma
  • Amneal Pharmaceuticals
  • Renata PLC
  • Qingdao Guoxin Pharmaceutical

按类型分類的细分市场

  • 原药
  • 学名药

应用领域

  • 医院和诊所
  • 零售药房
  • 其他的

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Frovatriptan Succinate Tablets was estimated to be worth US$ 31.15 million in 2024 and is forecast to a readjusted size of US$ 39.55 million by 2031 with a CAGR of 3.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Frovatriptan Succinate Tablets cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Frovatriptan Succinate Tablets are selective 5-HT1B/1D receptor agonists, primarily indicated for the treatment of acute migraine attacks. The upstream supply chain involves the synthesis of high-purity active pharmaceutical ingredients (APIs) and chemical intermediates, largely supplied by specialized API manufacturers in Europe and India. Pharmaceutical excipients such as lactose, starch, and microcrystalline cellulose are provided by leading global excipient suppliers.

Downstream customers mainly include neurology departments, headache specialty clinics, retail pharmacies, and online prescription platforms. With the growing population of migraine patients and the increasing demand for effective treatment, Frovatriptan Succinate Tablets are experiencing steady demand growth in both Western and Asian markets. Looking ahead, the rise of personalized medicine and telemedicine prescription services is expected to expand the applications of this drug in the global healthcare landscape.

In 2024, the global average price of Frovatriptan Succinate Tablets is approximately USD 3.74 per tablet, with total sales reaching around 8.33 million tablets.

At present, the global market for Frovatriptan Succinate Tablets demonstrates a dual structure of originator and generic products, positioning it as a mature niche within the triptan class of migraine therapeutics. In developed markets such as the U.S. and Europe, demand remains steady due to clinical guideline endorsements and broad reimbursement coverage. Meanwhile, in Asia-Pacific, particularly China and India, market penetration is accelerating, supported by the entry of local generic manufacturers that enhance affordability and accessibility. Overall, competition is largely driven by pricing strategies and distribution expansion.

From a manufacturing perspective, the production of Frovatriptan Succinate Tablets involves high-precision formulation processes. Common excipients include lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, sodium starch glycolate, magnesium stearate, and specialized film-coating premixes. These excipients are critical for ensuring stability, bioavailability, and patient adherence, underscoring the importance of strict quality control and adherence to CGMP standards. Companies such as Endo Pharmaceuticals, Menarini, Ingenus Pharmaceutical, and Glenmark operate advanced facilities and robust quality management systems to ensure consistent supply and regulatory compliance. The raw material supply chain is divided into APIs and excipients, each subject to rigorous pharmacopoeia testing, highlighting the complexities inherent in scaling up production and enabling global distribution.

Looking ahead, the market is expected to remain relatively stable with modest growth. On one hand, the rising prevalence of migraine and improved diagnosis and treatment rates in emerging markets will sustain demand. On the other hand, the adoption of novel therapies such as CGRP monoclonal antibodies and oral CGRP antagonists is exerting substitution pressure on traditional triptans. While Frovatriptan and related agents may gradually lose share in mature markets, they are expected to retain a strong position in cost-sensitive regions with limited healthcare coverage. Key growth drivers include continued inclusion of triptans in clinical guidelines, the increasing global burden of migraine, and the cost advantage of generics. However, the market faces challenges such as competitive threats from new therapeutic classes, stringent regulatory frameworks on pricing and prescription, and patient adherence issues linked to side effects and the need for combination therapies. Together, these dynamics define the opportunities and competitive landscape of the future market.

This report aims to provide a comprehensive presentation of the global market for Frovatriptan Succinate Tablets, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Frovatriptan Succinate Tablets by region & country, by Type, and by Application.

The Frovatriptan Succinate Tablets market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Frovatriptan Succinate Tablets.

Market Segmentation

By Company

  • Endo International
  • Menarini
  • Ingenus Pharmaceutical
  • Glenmark Pharmaceuticals
  • SK Chemicals
  • Teva
  • G.L. Pharma
  • Clydesdale Pharma
  • Amneal Pharmaceuticals
  • Renata PLC
  • Qingdao Guoxin Pharmaceutical

Segment by Type

  • Original Drug
  • Generic Drug

Segment by Application

  • Hospital and Clinic
  • Retail Pharmacies
  • Other

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Frovatriptan Succinate Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Frovatriptan Succinate Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Frovatriptan Succinate Tablets in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Frovatriptan Succinate Tablets Product Introduction
  • 1.2 Global Frovatriptan Succinate Tablets Market Size Forecast
    • 1.2.1 Global Frovatriptan Succinate Tablets Sales Value (2020-2031)
    • 1.2.2 Global Frovatriptan Succinate Tablets Sales Volume (2020-2031)
    • 1.2.3 Global Frovatriptan Succinate Tablets Sales Price (2020-2031)
  • 1.3 Frovatriptan Succinate Tablets Market Trends & Drivers
    • 1.3.1 Frovatriptan Succinate Tablets Industry Trends
    • 1.3.2 Frovatriptan Succinate Tablets Market Drivers & Opportunity
    • 1.3.3 Frovatriptan Succinate Tablets Market Challenges
    • 1.3.4 Frovatriptan Succinate Tablets Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Frovatriptan Succinate Tablets Players Revenue Ranking (2024)
  • 2.2 Global Frovatriptan Succinate Tablets Revenue by Company (2020-2025)
  • 2.3 Global Frovatriptan Succinate Tablets Players Sales Volume Ranking (2024)
  • 2.4 Global Frovatriptan Succinate Tablets Sales Volume by Company Players (2020-2025)
  • 2.5 Global Frovatriptan Succinate Tablets Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Frovatriptan Succinate Tablets Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Frovatriptan Succinate Tablets Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Frovatriptan Succinate Tablets
  • 2.9 Frovatriptan Succinate Tablets Market Competitive Analysis
    • 2.9.1 Frovatriptan Succinate Tablets Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Frovatriptan Succinate Tablets Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Frovatriptan Succinate Tablets as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Original Drug
    • 3.1.2 Generic Drug
  • 3.2 Global Frovatriptan Succinate Tablets Sales Value by Type
    • 3.2.1 Global Frovatriptan Succinate Tablets Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Frovatriptan Succinate Tablets Sales Value, by Type (2020-2031)
    • 3.2.3 Global Frovatriptan Succinate Tablets Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Frovatriptan Succinate Tablets Sales Volume by Type
    • 3.3.1 Global Frovatriptan Succinate Tablets Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Frovatriptan Succinate Tablets Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Frovatriptan Succinate Tablets Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Frovatriptan Succinate Tablets Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospital and Clinic
    • 4.1.2 Retail Pharmacies
    • 4.1.3 Other
  • 4.2 Global Frovatriptan Succinate Tablets Sales Value by Application
    • 4.2.1 Global Frovatriptan Succinate Tablets Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Frovatriptan Succinate Tablets Sales Value, by Application (2020-2031)
    • 4.2.3 Global Frovatriptan Succinate Tablets Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Frovatriptan Succinate Tablets Sales Volume by Application
    • 4.3.1 Global Frovatriptan Succinate Tablets Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Frovatriptan Succinate Tablets Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Frovatriptan Succinate Tablets Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Frovatriptan Succinate Tablets Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Frovatriptan Succinate Tablets Sales Value by Region
    • 5.1.1 Global Frovatriptan Succinate Tablets Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Frovatriptan Succinate Tablets Sales Value by Region (2020-2025)
    • 5.1.3 Global Frovatriptan Succinate Tablets Sales Value by Region (2026-2031)
    • 5.1.4 Global Frovatriptan Succinate Tablets Sales Value by Region (%), (2020-2031)
  • 5.2 Global Frovatriptan Succinate Tablets Sales Volume by Region
    • 5.2.1 Global Frovatriptan Succinate Tablets Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Frovatriptan Succinate Tablets Sales Volume by Region (2020-2025)
    • 5.2.3 Global Frovatriptan Succinate Tablets Sales Volume by Region (2026-2031)
    • 5.2.4 Global Frovatriptan Succinate Tablets Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Frovatriptan Succinate Tablets Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 5.4.2 North America Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 5.5.2 Europe Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Frovatriptan Succinate Tablets Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 5.7.2 South America Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Frovatriptan Succinate Tablets Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Frovatriptan Succinate Tablets Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Frovatriptan Succinate Tablets Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 6.3.2 United States Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 6.4.2 Europe Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 6.5.2 China Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 6.6.2 Japan Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 6.7.2 South Korea Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Frovatriptan Succinate Tablets Sales Value, 2020-2031
    • 6.9.2 India Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Frovatriptan Succinate Tablets Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Endo International
    • 7.1.1 Endo International Company Information
    • 7.1.2 Endo International Introduction and Business Overview
    • 7.1.3 Endo International Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Endo International Frovatriptan Succinate Tablets Product Offerings
    • 7.1.5 Endo International Recent Development
  • 7.2 Menarini
    • 7.2.1 Menarini Company Information
    • 7.2.2 Menarini Introduction and Business Overview
    • 7.2.3 Menarini Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Menarini Frovatriptan Succinate Tablets Product Offerings
    • 7.2.5 Menarini Recent Development
  • 7.3 Ingenus Pharmaceutical
    • 7.3.1 Ingenus Pharmaceutical Company Information
    • 7.3.2 Ingenus Pharmaceutical Introduction and Business Overview
    • 7.3.3 Ingenus Pharmaceutical Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Ingenus Pharmaceutical Frovatriptan Succinate Tablets Product Offerings
    • 7.3.5 Ingenus Pharmaceutical Recent Development
  • 7.4 Glenmark Pharmaceuticals
    • 7.4.1 Glenmark Pharmaceuticals Company Information
    • 7.4.2 Glenmark Pharmaceuticals Introduction and Business Overview
    • 7.4.3 Glenmark Pharmaceuticals Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Glenmark Pharmaceuticals Frovatriptan Succinate Tablets Product Offerings
    • 7.4.5 Glenmark Pharmaceuticals Recent Development
  • 7.5 SK Chemicals
    • 7.5.1 SK Chemicals Company Information
    • 7.5.2 SK Chemicals Introduction and Business Overview
    • 7.5.3 SK Chemicals Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 SK Chemicals Frovatriptan Succinate Tablets Product Offerings
    • 7.5.5 SK Chemicals Recent Development
  • 7.6 Teva
    • 7.6.1 Teva Company Information
    • 7.6.2 Teva Introduction and Business Overview
    • 7.6.3 Teva Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Teva Frovatriptan Succinate Tablets Product Offerings
    • 7.6.5 Teva Recent Development
  • 7.7 G.L. Pharma
    • 7.7.1 G.L. Pharma Company Information
    • 7.7.2 G.L. Pharma Introduction and Business Overview
    • 7.7.3 G.L. Pharma Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 G.L. Pharma Frovatriptan Succinate Tablets Product Offerings
    • 7.7.5 G.L. Pharma Recent Development
  • 7.8 Clydesdale Pharma
    • 7.8.1 Clydesdale Pharma Company Information
    • 7.8.2 Clydesdale Pharma Introduction and Business Overview
    • 7.8.3 Clydesdale Pharma Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Clydesdale Pharma Frovatriptan Succinate Tablets Product Offerings
    • 7.8.5 Clydesdale Pharma Recent Development
  • 7.9 Amneal Pharmaceuticals
    • 7.9.1 Amneal Pharmaceuticals Company Information
    • 7.9.2 Amneal Pharmaceuticals Introduction and Business Overview
    • 7.9.3 Amneal Pharmaceuticals Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 Amneal Pharmaceuticals Frovatriptan Succinate Tablets Product Offerings
    • 7.9.5 Amneal Pharmaceuticals Recent Development
  • 7.10 Renata PLC
    • 7.10.1 Renata PLC Company Information
    • 7.10.2 Renata PLC Introduction and Business Overview
    • 7.10.3 Renata PLC Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 Renata PLC Frovatriptan Succinate Tablets Product Offerings
    • 7.10.5 Renata PLC Recent Development
  • 7.11 Qingdao Guoxin Pharmaceutical
    • 7.11.1 Qingdao Guoxin Pharmaceutical Company Information
    • 7.11.2 Qingdao Guoxin Pharmaceutical Introduction and Business Overview
    • 7.11.3 Qingdao Guoxin Pharmaceutical Frovatriptan Succinate Tablets Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.11.4 Qingdao Guoxin Pharmaceutical Frovatriptan Succinate Tablets Product Offerings
    • 7.11.5 Qingdao Guoxin Pharmaceutical Recent Development

8 Industry Chain Analysis

  • 8.1 Frovatriptan Succinate Tablets Industrial Chain
  • 8.2 Frovatriptan Succinate Tablets Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Frovatriptan Succinate Tablets Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Frovatriptan Succinate Tablets Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Frovatriptan Succinate Tablets Market Trends
  • Table 2. Frovatriptan Succinate Tablets Market Drivers & Opportunity
  • Table 3. Frovatriptan Succinate Tablets Market Challenges
  • Table 4. Frovatriptan Succinate Tablets Market Restraints
  • Table 5. Global Frovatriptan Succinate Tablets Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Frovatriptan Succinate Tablets Revenue Market Share by Company (2020-2025)
  • Table 7. Global Frovatriptan Succinate Tablets Sales Volume by Company (2020-2025) & (K Units)
  • Table 8. Global Frovatriptan Succinate Tablets Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Frovatriptan Succinate Tablets Price by Company (2020-2025) & (US$/Unit)
  • Table 10. Key Manufacturers Frovatriptan Succinate Tablets Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Frovatriptan Succinate Tablets Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Frovatriptan Succinate Tablets
  • Table 13. Global Frovatriptan Succinate Tablets Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Frovatriptan Succinate Tablets as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Frovatriptan Succinate Tablets Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Frovatriptan Succinate Tablets Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Frovatriptan Succinate Tablets Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Frovatriptan Succinate Tablets Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Frovatriptan Succinate Tablets Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Frovatriptan Succinate Tablets Sales Volume by Type: 2020 VS 2024 VS 2031 (K Units)
  • Table 22. Global Frovatriptan Succinate Tablets Sales Volume by Type (2020-2025) & (K Units)
  • Table 23. Global Frovatriptan Succinate Tablets Sales Volume by Type (2026-2031) & (K Units)
  • Table 24. Global Frovatriptan Succinate Tablets Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Frovatriptan Succinate Tablets Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Frovatriptan Succinate Tablets Price by Type (2020-2025) & (US$/Unit)
  • Table 27. Global Frovatriptan Succinate Tablets Price by Type (2026-2031) & (US$/Unit)
  • Table 28. Global Frovatriptan Succinate Tablets Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Frovatriptan Succinate Tablets Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Frovatriptan Succinate Tablets Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Frovatriptan Succinate Tablets Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Frovatriptan Succinate Tablets Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Frovatriptan Succinate Tablets Sales Volume by Application: 2020 VS 2024 VS 2031 (K Units)
  • Table 34. Global Frovatriptan Succinate Tablets Sales Volume by Application (2020-2025) & (K Units)
  • Table 35. Global Frovatriptan Succinate Tablets Sales Volume by Application (2026-2031) & (K Units)
  • Table 36. Global Frovatriptan Succinate Tablets Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Frovatriptan Succinate Tablets Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Frovatriptan Succinate Tablets Price by Application (2020-2025) & (US$/Unit)
  • Table 39. Global Frovatriptan Succinate Tablets Price by Application (2026-2031) & (US$/Unit)
  • Table 40. Global Frovatriptan Succinate Tablets Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Frovatriptan Succinate Tablets Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Frovatriptan Succinate Tablets Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Frovatriptan Succinate Tablets Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Frovatriptan Succinate Tablets Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Frovatriptan Succinate Tablets Sales Volume by Region (K Units): 2020 VS 2024 VS 2031
  • Table 46. Global Frovatriptan Succinate Tablets Sales Volume by Region (2020-2025) & (K Units)
  • Table 47. Global Frovatriptan Succinate Tablets Sales Volume by Region (2026-2031) & (K Units)
  • Table 48. Global Frovatriptan Succinate Tablets Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Frovatriptan Succinate Tablets Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Frovatriptan Succinate Tablets Average Price by Region (2020-2025) & (US$/Unit)
  • Table 51. Global Frovatriptan Succinate Tablets Average Price by Region (2026-2031) & (US$/Unit)
  • Table 52. Key Countries/Regions Frovatriptan Succinate Tablets Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Frovatriptan Succinate Tablets Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Frovatriptan Succinate Tablets Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Frovatriptan Succinate Tablets Sales Volume, (2020-2025) & (K Units)
  • Table 56. Key Countries/Regions Frovatriptan Succinate Tablets Sales Volume, (2026-2031) & (K Units)
  • Table 57. Endo International Company Information
  • Table 58. Endo International Introduction and Business Overview
  • Table 59. Endo International Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 60. Endo International Frovatriptan Succinate Tablets Product Offerings
  • Table 61. Endo International Recent Development
  • Table 62. Menarini Company Information
  • Table 63. Menarini Introduction and Business Overview
  • Table 64. Menarini Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 65. Menarini Frovatriptan Succinate Tablets Product Offerings
  • Table 66. Menarini Recent Development
  • Table 67. Ingenus Pharmaceutical Company Information
  • Table 68. Ingenus Pharmaceutical Introduction and Business Overview
  • Table 69. Ingenus Pharmaceutical Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 70. Ingenus Pharmaceutical Frovatriptan Succinate Tablets Product Offerings
  • Table 71. Ingenus Pharmaceutical Recent Development
  • Table 72. Glenmark Pharmaceuticals Company Information
  • Table 73. Glenmark Pharmaceuticals Introduction and Business Overview
  • Table 74. Glenmark Pharmaceuticals Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 75. Glenmark Pharmaceuticals Frovatriptan Succinate Tablets Product Offerings
  • Table 76. Glenmark Pharmaceuticals Recent Development
  • Table 77. SK Chemicals Company Information
  • Table 78. SK Chemicals Introduction and Business Overview
  • Table 79. SK Chemicals Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 80. SK Chemicals Frovatriptan Succinate Tablets Product Offerings
  • Table 81. SK Chemicals Recent Development
  • Table 82. Teva Company Information
  • Table 83. Teva Introduction and Business Overview
  • Table 84. Teva Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 85. Teva Frovatriptan Succinate Tablets Product Offerings
  • Table 86. Teva Recent Development
  • Table 87. G.L. Pharma Company Information
  • Table 88. G.L. Pharma Introduction and Business Overview
  • Table 89. G.L. Pharma Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 90. G.L. Pharma Frovatriptan Succinate Tablets Product Offerings
  • Table 91. G.L. Pharma Recent Development
  • Table 92. Clydesdale Pharma Company Information
  • Table 93. Clydesdale Pharma Introduction and Business Overview
  • Table 94. Clydesdale Pharma Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 95. Clydesdale Pharma Frovatriptan Succinate Tablets Product Offerings
  • Table 96. Clydesdale Pharma Recent Development
  • Table 97. Amneal Pharmaceuticals Company Information
  • Table 98. Amneal Pharmaceuticals Introduction and Business Overview
  • Table 99. Amneal Pharmaceuticals Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 100. Amneal Pharmaceuticals Frovatriptan Succinate Tablets Product Offerings
  • Table 101. Amneal Pharmaceuticals Recent Development
  • Table 102. Renata PLC Company Information
  • Table 103. Renata PLC Introduction and Business Overview
  • Table 104. Renata PLC Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 105. Renata PLC Frovatriptan Succinate Tablets Product Offerings
  • Table 106. Renata PLC Recent Development
  • Table 107. Qingdao Guoxin Pharmaceutical Company Information
  • Table 108. Qingdao Guoxin Pharmaceutical Introduction and Business Overview
  • Table 109. Qingdao Guoxin Pharmaceutical Frovatriptan Succinate Tablets Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
  • Table 110. Qingdao Guoxin Pharmaceutical Frovatriptan Succinate Tablets Product Offerings
  • Table 111. Qingdao Guoxin Pharmaceutical Recent Development
  • Table 112. Key Raw Materials Lists
  • Table 113. Raw Materials Key Suppliers Lists
  • Table 114. Frovatriptan Succinate Tablets Downstream Customers
  • Table 115. Frovatriptan Succinate Tablets Distributors List
  • Table 116. Research Programs/Design for This Report
  • Table 117. Key Data Information from Secondary Sources
  • Table 118. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Frovatriptan Succinate Tablets Product Picture
  • Figure 2. Global Frovatriptan Succinate Tablets Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Frovatriptan Succinate Tablets Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Frovatriptan Succinate Tablets Sales Volume (2020-2031) & (K Units)
  • Figure 5. Global Frovatriptan Succinate Tablets Sales Price (2020-2031) & (US$/Unit)
  • Figure 6. Frovatriptan Succinate Tablets Report Years Considered
  • Figure 7. Global Frovatriptan Succinate Tablets Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Frovatriptan Succinate Tablets Players Sales Volume Ranking (2024) & (K Units)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Frovatriptan Succinate Tablets Revenue in 2024
  • Figure 10. Frovatriptan Succinate Tablets Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. Original Drug Picture
  • Figure 12. Generic Drug Picture
  • Figure 13. Global Frovatriptan Succinate Tablets Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 14. Global Frovatriptan Succinate Tablets Sales Value Market Share by Type, 2024 & 2031
  • Figure 15. Global Frovatriptan Succinate Tablets Sales Volume by Type (2020 VS 2024 VS 2031) & (K Units)
  • Figure 16. Global Frovatriptan Succinate Tablets Sales Volume Market Share by Type, 2024 & 2031
  • Figure 17. Global Frovatriptan Succinate Tablets Price by Type (2020-2031) & (US$/Unit)
  • Figure 18. Product Picture of Hospital and Clinic
  • Figure 19. Product Picture of Retail Pharmacies
  • Figure 20. Product Picture of Other
  • Figure 21. Global Frovatriptan Succinate Tablets Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 22. Global Frovatriptan Succinate Tablets Sales Value Market Share by Application, 2024 & 2031
  • Figure 23. Global Frovatriptan Succinate Tablets Sales Volume by Application (2020 VS 2024 VS 2031) & (K Units)
  • Figure 24. Global Frovatriptan Succinate Tablets Sales Volume Market Share by Application, 2024 & 2031
  • Figure 25. Global Frovatriptan Succinate Tablets Price by Application (2020-2031) & (US$/Unit)
  • Figure 26. North America Frovatriptan Succinate Tablets Sales Value (2020-2031) & (US$ Million)
  • Figure 27. North America Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Europe Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. Europe Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Asia Pacific Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Asia Pacific Frovatriptan Succinate Tablets Sales Value by Region (%), 2024 VS 2031
  • Figure 32. South America Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. South America Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031
  • Figure 34. Middle East & Africa Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Middle East & Africa Frovatriptan Succinate Tablets Sales Value by Country (%), 2024 VS 2031
  • Figure 36. Key Countries/Regions Frovatriptan Succinate Tablets Sales Value (%), (2020-2031)
  • Figure 37. Key Countries/Regions Frovatriptan Succinate Tablets Sales Volume (%), (2020-2031)
  • Figure 38. United States Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. United States Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • Figure 40. United States Frovatriptan Succinate Tablets Sales Value by Application (%), 2024 VS 2031
  • Figure 41. Europe Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. Europe Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • Figure 43. Europe Frovatriptan Succinate Tablets Sales Value by Application (%), 2024 VS 2031
  • Figure 44. China Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. China Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • Figure 46. China Frovatriptan Succinate Tablets Sales Value by Application (%), 2024 VS 2031
  • Figure 47. Japan Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. Japan Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • Figure 49. Japan Frovatriptan Succinate Tablets Sales Value by Application (%), 2024 VS 2031
  • Figure 50. South Korea Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 51. South Korea Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • Figure 52. South Korea Frovatriptan Succinate Tablets Sales Value by Application (%), 2024 VS 2031
  • Figure 53. Southeast Asia Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 54. Southeast Asia Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • Figure 55. Southeast Asia Frovatriptan Succinate Tablets Sales Value by Application (%), 2024 VS 2031
  • Figure 56. India Frovatriptan Succinate Tablets Sales Value, (2020-2031) & (US$ Million)
  • Figure 57. India Frovatriptan Succinate Tablets Sales Value by Type (%), 2024 VS 2031
  • Figure 58. India Frovatriptan Succinate Tablets Sales Value by Application (%), 2024 VS 2031
  • Figure 59. Frovatriptan Succinate Tablets Industrial Chain
  • Figure 60. Frovatriptan Succinate Tablets Manufacturing Cost Structure
  • Figure 61. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 62. Bottom-up and Top-down Approaches for This Report
  • Figure 63. Data Triangulation
  • Figure 64. Key Executives Interviewed